The Zacks Analyst Blog Highlights IBB, XBI, BBH and GNOM
IBB and peers are gaining traction as AI transforms biotech, boosting drug discovery, trials and growth prospects across diversified ETF portfolios.
Zacks·19d ago
More News
Beyond Tech Industry: Here's how Biotech ETFs Are Riding the AI Wave
IBB and other biotech ETFs are gaining traction as AI reshapes drug discovery, genomics, and clinical trials, giving investors diversified exposure to biotech innovation.
Zacks·20d ago
Should You Invest in the VanEck Biotech ETF (BBH)?
Sector ETF report for BBH
Zacks·26d ago
PLRZ Stock Jumps 6% In Pre-Market – Why Is This Biotech Firm Diversifying Into Aviation Business?
The company announced that it recently signed an MoU to acquire a 51% stake in private aviation firm Arrow Aviation for around $5.8 million.
Stocktwits·2mo ago
Regeneron’s New Growth Engine Is Starting To Show – But Core Eylea Weakness Weighs On REGN Stock
Fourth-quarter revenue increased 3% from a year earlier to $3.88 billion, topping Wall Street expectations of $3.78 billion, according to Fiscal.ai data.
Stocktwits·2mo ago
Should You Invest in the VanEck Biotech ETF (BBH)?
Sector ETF report for BBH
Zacks·3mo ago
VanEck Announces Year-End Distributions for VanEck Equity ETFs
VanEck announced today the following 2025 annual distributions per share for its VanEck equity exchange-traded funds. Distributions Per Share for the VanEck ETFs Listed Below Ex-Date: December 22...
Business Wire·4mo ago
Should You Invest in the VanEck Biotech ETF (BBH)?
Sector ETF report for BBH
Zacks·9mo ago
Are Wall Street Analysts Predicting Vertex Pharmaceuticals Stock Will Climb or Sink?
Vertex Pharmaceuticals has lagged behind the broader market over the past year, and Wall Street analysts are cautiously optimistic about the stock’s future.